S&P 500   3,343.16 (-0.25%)
DOW   27,509.09 (-0.27%)
QQQ   276.70 (-0.18%)
AAPL   114.22 (-0.64%)
MSFT   207.72 (-0.82%)
FB   259.43 (+1.02%)
GOOGL   1,460.64 (+0.14%)
AMZN   3,159.10 (-0.47%)
TSLA   426.86 (+1.34%)
NVDA   533.34 (+2.29%)
BABA   277.31 (+0.47%)
CGC   14.45 (+1.69%)
GE   6.10 (-1.61%)
MU   51.02 (+2.61%)
AMD   82.16 (+3.37%)
T   28.29 (-0.32%)
F   6.59 (-1.49%)
ACB   4.76 (-0.42%)
GILD   62.18 (-1.07%)
NFLX   493.89 (+0.66%)
DIS   124.75 (-0.98%)
BA   163.64 (-1.47%)
BAC   23.79 (-1.25%)
S&P 500   3,343.16 (-0.25%)
DOW   27,509.09 (-0.27%)
QQQ   276.70 (-0.18%)
AAPL   114.22 (-0.64%)
MSFT   207.72 (-0.82%)
FB   259.43 (+1.02%)
GOOGL   1,460.64 (+0.14%)
AMZN   3,159.10 (-0.47%)
TSLA   426.86 (+1.34%)
NVDA   533.34 (+2.29%)
BABA   277.31 (+0.47%)
CGC   14.45 (+1.69%)
GE   6.10 (-1.61%)
MU   51.02 (+2.61%)
AMD   82.16 (+3.37%)
T   28.29 (-0.32%)
F   6.59 (-1.49%)
ACB   4.76 (-0.42%)
GILD   62.18 (-1.07%)
NFLX   493.89 (+0.66%)
DIS   124.75 (-0.98%)
BA   163.64 (-1.47%)
BAC   23.79 (-1.25%)
S&P 500   3,343.16 (-0.25%)
DOW   27,509.09 (-0.27%)
QQQ   276.70 (-0.18%)
AAPL   114.22 (-0.64%)
MSFT   207.72 (-0.82%)
FB   259.43 (+1.02%)
GOOGL   1,460.64 (+0.14%)
AMZN   3,159.10 (-0.47%)
TSLA   426.86 (+1.34%)
NVDA   533.34 (+2.29%)
BABA   277.31 (+0.47%)
CGC   14.45 (+1.69%)
GE   6.10 (-1.61%)
MU   51.02 (+2.61%)
AMD   82.16 (+3.37%)
T   28.29 (-0.32%)
F   6.59 (-1.49%)
ACB   4.76 (-0.42%)
GILD   62.18 (-1.07%)
NFLX   493.89 (+0.66%)
DIS   124.75 (-0.98%)
BA   163.64 (-1.47%)
BAC   23.79 (-1.25%)
S&P 500   3,343.16 (-0.25%)
DOW   27,509.09 (-0.27%)
QQQ   276.70 (-0.18%)
AAPL   114.22 (-0.64%)
MSFT   207.72 (-0.82%)
FB   259.43 (+1.02%)
GOOGL   1,460.64 (+0.14%)
AMZN   3,159.10 (-0.47%)
TSLA   426.86 (+1.34%)
NVDA   533.34 (+2.29%)
BABA   277.31 (+0.47%)
CGC   14.45 (+1.69%)
GE   6.10 (-1.61%)
MU   51.02 (+2.61%)
AMD   82.16 (+3.37%)
T   28.29 (-0.32%)
F   6.59 (-1.49%)
ACB   4.76 (-0.42%)
GILD   62.18 (-1.07%)
NFLX   493.89 (+0.66%)
DIS   124.75 (-0.98%)
BA   163.64 (-1.47%)
BAC   23.79 (-1.25%)
Log in
NASDAQ:ANIK

Anika Therapeutics Stock Forecast, Price & News

$34.36
-0.98 (-2.77 %)
(As of 09/29/2020 02:03 PM ET)
Add
Compare
Today's Range
$33.84
Now: $34.36
$35.31
50-Day Range
$32.56
MA: $36.22
$38.33
52-Week Range
$22.01
Now: $34.36
$75.71
Volume1,081 shs
Average Volume163,993 shs
Market Capitalization$488.15 million
P/E Ratio55.42
Dividend YieldN/A
Beta1.11
Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a resorbable knitted fabric mesh; HYALOSS MATRIX, HYAFF fibers used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. The company's dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
Read More
Anika Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.73 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:ANIK
CUSIP03525510
Phone781-457-9000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$114.51 million
Cash Flow$2.52 per share
Book Value$20.21 per share

Profitability

Net Income$27.19 million

Miscellaneous

Employees133
Market Cap$488.15 million
Next Earnings Date10/22/2020 (Estimated)
OptionableOptionable
$34.36
-0.98 (-2.77 %)
(As of 09/29/2020 02:03 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ANIK News and Ratings via Email

Sign-up to receive the latest news and ratings for ANIK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Anika Therapeutics (NASDAQ:ANIK) Frequently Asked Questions

How has Anika Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Anika Therapeutics' stock was trading at $36.39 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ANIK shares have decreased by 5.8% and is now trading at $34.28.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Anika Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating, 1 buy rating and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Anika Therapeutics
.

When is Anika Therapeutics' next earnings date?

Anika Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, October 22nd 2020.
View our earnings forecast for Anika Therapeutics
.

How were Anika Therapeutics' earnings last quarter?

Anika Therapeutics Inc (NASDAQ:ANIK) issued its quarterly earnings data on Thursday, July, 30th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by $0.33. The biotechnology company earned $30.68 million during the quarter, compared to the consensus estimate of $16.73 million. Anika Therapeutics had a net margin of 7.17% and a return on equity of 8.05%.
View Anika Therapeutics' earnings history
.

What price target have analysts set for ANIK?

4 brokers have issued 12 month target prices for Anika Therapeutics' stock. Their forecasts range from $29.00 to $65.00. On average, they expect Anika Therapeutics' share price to reach $53.75 in the next twelve months. This suggests a possible upside of 56.8% from the stock's current price.
View analysts' price targets for Anika Therapeutics
.

Who are some of Anika Therapeutics' key competitors?

What other stocks do shareholders of Anika Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Alibaba Group (BABA), Broadcom (AVGO), Gilead Sciences (GILD), Micron Technology (MU), Skyworks Solutions (SWKS), Tesla (TSLA), Advanced Micro Devices (AMD), CVS Health (CVS), Enterprise Products Partners (EPD) and Ligand Pharmaceuticals (LGND).

Who are Anika Therapeutics' key executives?

Anika Therapeutics' management team includes the following people:
  • Mr. Joseph G. Darling, CEO, Pres & Director (Age 61)
  • Ms. Sylvia Cheung, CFO, Treasurer & Sec. (Age 44)
  • Dr. Edward S. Ahn, Chief Technology & Strategy Officer (Age 47)
  • Mr. Thomas M. Finnerty, Chief HR Officer (Age 61)
  • Mr. Alexei Goraltchouk, VP of Operations

What is Anika Therapeutics' stock symbol?

Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."

How do I buy shares of Anika Therapeutics?

Shares of ANIK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Anika Therapeutics' stock price today?

One share of ANIK stock can currently be purchased for approximately $34.28.

How big of a company is Anika Therapeutics?

Anika Therapeutics has a market capitalization of $487.02 million and generates $114.51 million in revenue each year. The biotechnology company earns $27.19 million in net income (profit) each year or $2.05 on an earnings per share basis. Anika Therapeutics employs 133 workers across the globe.

What is Anika Therapeutics' official website?

The official website for Anika Therapeutics is www.anikatherapeutics.com.

How can I contact Anika Therapeutics?

Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The biotechnology company can be reached via phone at 781-457-9000 or via email at [email protected]

This page was last updated on 9/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.